Literature DB >> 933300

Urinary ascites secondary to posterior urethral valves.

T W Scott.   

Abstract

Neonatal urinary ascites demands prompt diagnostic and therapeutic medical attention. Obstructing posterior urethral valves are a major cause (70 per cent) of this entity. Survival in these children can be directly related to age, selection of therapeutic modality and the presence or absence of associated pulmonary and electrolyte abnormalities. Oligohydramnios is implicated in the production of pulmonary hypoplasia leading to respiratory distress in these patients. Other manifestations of prolonged, increased fetal compression, that is the non-renal features of Potter's syndrome, include altered facies, aberrant hand and foot development and late fetal growth deficiency. Aberrant pulmonary development seems to be related to increased intrauterine pressure (oligohydramnios alone) as well as increased fetal intra-abdominal pressure (oligohydramnios plus urinary ascites). The best therapeutic results were achieved in those children treated by early, high urinary diversion. The mortality rate for newborns less than 72 hours old was significantly higher (66 per cent) than for those more than 72 hours old (15 per cent).

Entities:  

Mesh:

Year:  1976        PMID: 933300     DOI: 10.1016/s0022-5347(17)58691-7

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  3 in total

1.  Spontaneous bladder rupture secondary to posterior urethral valves in a neonate.

Authors:  P Arora; A Seth; D Bagga; S Aneja; V Taluja
Journal:  Indian J Pediatr       Date:  2001-09       Impact factor: 1.967

2.  Urinoma formation in posterior urethral valves: relationship to later renal function.

Authors:  S K Fernbach; K A Feinstein; M R Zaontz
Journal:  Pediatr Radiol       Date:  1990

Review 3.  Acute perirenal extravasation of urine in an infant with non-refluxing megaureter.

Authors:  Rolf Beetz; Raimund Stein; Petra Rohatsch; Rita Brzezinska; Jochen W Thüroff
Journal:  Pediatr Nephrol       Date:  2003-12-18       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.